See more : Primaris Real Estate Investment Trust (PMREF) Income Statement Analysis – Financial Results
Complete financial analysis of Mydecine Innovations Group Inc. (MYCO.NE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Mydecine Innovations Group Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Samsung Heavy Industries Co., Ltd. (010140.KS) Income Statement Analysis – Financial Results
- Fly Play hf. (PLAY.IC) Income Statement Analysis – Financial Results
- Cygnus Gold Limited (CY5.AX) Income Statement Analysis – Financial Results
- Arabian International Healthcare Holding Company (9530.SR) Income Statement Analysis – Financial Results
- International Paper Company (INP.DE) Income Statement Analysis – Financial Results
Mydecine Innovations Group Inc. (MYCO.NE)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.mydecine.com
About Mydecine Innovations Group Inc.
Mydecine Innovations Group Inc., a biotech and life sciences company, engages in the development and commercialization of drugs for treating mental health problems. It develops therapies for veterans, emergency medical service providers, post-traumatic stress disorder, and front-line workers; and operates Mindleap, a digital telehealth platform that provides access to mental health services, as well as psychedelic integration services, including psychedelic aftercare and wellness services. The company also engages in the drug discovery and builds nature-sourced psychedelic-assisted therapeutics, compounds, therapy protocols, and unique delivery systems. In addition, it operates hemp farm in Pottus, Texas. Mydecine Innovations Group Inc. has a partnership with Leiden University Medical Center; Royal Ottawa Mental Health Centre; LeadGen Labs to support psychedelic drug development; and Applied Pharmaceutical Innovation for drug development and clinical trial programs. The company was formerly known as NewLeaf Brands Inc. and changed its name to Mydecine Innovations Group Inc. in June 2020. Mydecine Innovations Group Inc. was incorporated in 2013 and is headquartered in Vancouver, Canada.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 7.49K | 58.49K | 125.57K | 207.66K | 0.00 | 0.00 | 84.00K | 84.00K | 49.00K |
| Cost of Revenue | 0.00 | 0.00 | 37.37K | 94.05K | 109.82K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 7.49K | 21.12K | 31.52K | 97.83K | 0.00 | 0.00 | 84.00K | 84.00K | 49.00K |
| Gross Profit Ratio | 0.00% | 100.00% | 36.11% | 25.10% | 47.11% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 3.59M | 3.96M | 1.29M | 0.00 | 0.00 | 0.00 | 0.00 | 1.05K | 0.00 | 0.00 |
| General & Administrative | 9.98M | 14.74M | 7.74M | 3.27M | 4.88M | 14.62M | 3.92M | 3.64M | 808.13K | 46.40K |
| Selling & Marketing | 0.00 | 0.00 | 2.33M | 71.51K | 730.22K | 693.83K | 259.75K | 41.10K | 14.00K | 0.00 |
| SG&A | 9.98M | 14.74M | 10.07M | 3.34M | 5.61M | 15.31M | 4.18M | 3.68M | 822.13K | 46.40K |
| Other Expenses | 341.18K | -382.90K | 91.68K | 151.20K | -4.54M | -97.92K | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 16.39M | 22.69M | 11.65M | 3.49M | 5.90M | 15.70M | 4.19M | 3.81M | 929.46K | 73.26K |
| Cost & Expenses | 16.39M | 22.69M | 11.69M | 3.58M | 6.01M | 15.70M | 4.19M | 3.81M | 929.46K | 73.26K |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 18.62K | 0.00 | 0.00 | 75.00 | 7.00 | 102.00 |
| Interest Expense | 911.59K | 205.27K | 182.87K | 68.31K | 69.95K | 6.90K | 47.42K | 107.13K | 30.02K | 32.88K |
| Depreciation & Amortization | 128.86K | 235.18K | 90.20K | 109.08K | 21.76K | 246.58K | 9.00K | 24.56K | 25.05K | 25.70K |
| EBITDA | -15.71M | -22.19M | -11.24M | -3.21M | -5.52M | -15.46M | -4.16M | -3.56M | -736.09K | 1.44K |
| EBITDA Ratio | 0.00% | -304,709.21% | -19,007.40% | -2,555.37% | -2,782.25% | 0.00% | 0.00% | -4,582.18% | -976.67% | 3.14% |
| Operating Income | -16.05M | -23.07M | -11.21M | -3.32M | -5.80M | -15.70M | 4.19M | 3.72M | 1.11M | 24.16K |
| Operating Income Ratio | 0.00% | -307,847.83% | -19,161.62% | -2,642.24% | -2,792.73% | 0.00% | 0.00% | 4,430.54% | 1,320.65% | 49.31% |
| Total Other Income/Expenses | -1.53M | -1.48M | -15.75M | -200.82K | -7.84M | -2.25M | -3.80M | -267.48K | -490.55K | -110.20K |
| Income Before Tax | -17.24M | -23.58M | -26.95M | -3.51M | -13.36M | -17.56M | -7.96M | -4.64M | -1.23M | -107.60K |
| Income Before Tax Ratio | 0.00% | -314,732.56% | -46,074.45% | -2,793.41% | -6,431.45% | 0.00% | 0.00% | -5,524.04% | -1,458.97% | -219.59% |
| Income Tax Expense | -4.42M | 5.14M | 608.14K | 219.51K | 69.95K | 6.90K | -306.19K | 107.13K | 30.02K | 32.88K |
| Net Income | -11.57M | -28.90M | -26.95M | -3.51M | -13.36M | -17.56M | -7.60M | -4.64M | -1.23M | -107.60K |
| Net Income Ratio | 0.00% | -385,658.60% | -46,074.45% | -2,793.41% | -6,431.45% | 0.00% | 0.00% | -5,524.04% | -1,458.97% | -219.59% |
| EPS | -1.34 | -6.17 | -11.85 | -7.87 | -122.07 | -311.15 | -243.37 | -191.20 | -58.15 | -44.08 |
| EPS Diluted | -1.34 | -6.17 | -11.85 | -7.87 | -122.07 | -311.15 | -243.37 | -191.20 | -58.15 | -44.08 |
| Weighted Avg Shares Out | 8.65M | 4.68M | 2.27M | 445.47K | 109.41K | 56.43K | 31.25K | 24.27K | 21.08K | 2.44K |
| Weighted Avg Shares Out (Dil) | 8.65M | 4.68M | 2.27M | 445.47K | 109.41K | 56.43K | 31.25K | 24.27K | 21.08K | 2.44K |
Source: https://incomestatements.info
Category: Stock Reports